Hemostemix Inc. (CVE:HEM – Get Free Report)’s stock price was up 64.3% during mid-day trading on Tuesday . The company traded as high as C$0.12 and last traded at C$0.12. Approximately 532,088 shares changed hands during trading, an increase of 455% from the average daily volume of 95,884 shares. The stock had previously closed at C$0.07.
Hemostemix Price Performance
The firm has a 50-day moving average of C$0.08 and a 200 day moving average of C$0.07. The company has a market capitalization of C$10.02 million, a PE ratio of -5.75 and a beta of 0.20.
About Hemostemix
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Further Reading
- Five stocks we like better than Hemostemix
- 3 Monster Growth Stocks to Buy Now
- 3 Stocks Helping to Bring AI to Healthcare
- What Are the FAANG Stocks and Are They Good Investments?
- 3 Stocks Ringing in The New Year With Large Buyback Announcements
- What Are Dividend Contenders? Investing in Dividend Contenders
- Why 2024 Was Great for Stocks—and Why 2025 Could Be Even Better
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
